hema.to

Founded 2021
Employees 15+
Primary contact
Ainmillerstr. 22
80801 Munich
Germany
Diseases & Conditions
hema.to provides fully automated, AI-powered diagnosis recommendations for blood cancer from flow cytometry data. This, in turn, increases efficiency and quality for hemato-oncology labs using hema.to's cloud-based platform. In order to use it, diagnosticians upload flow data files, and the solution provides them with clinical indications and diagnostic recommendations, which follow expert consensus.
Founded 2021
Employees 15+
Primary contact
Ainmillerstr. 22
80801 Munich
Germany
Diseases & Conditions

Funding πŸ’°

Total €3.6M
Last round πŸ”— €3.6M
Seed
June 26, 2023.
Select investors Heal Capital, High-Tech Grunderfonds (HTGF), Elaia

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • Solving the problem: Cytometry, the clinical analysis of blood data, is a time-consuming exercise, coupled with shortages in laboratory staff, there was much scope for the system to be improved upon. hema.to wants to improve the system by using its cloud-based machine learning platform to personalize the analysis and bring "precision diagnostics to immune medicine."
  • Scientifically backed: In a series of papers, the company has demonstrated that its core AI algorithms are capable of hematologist-level B-NHL classifications and that this knowledge can be transferred across different flow protocols. πŸ”—
  • Demonstrated quality: Medical software requires development processes that meet the highest standards. hema.to is a CE-IVD product and is scientifically backed by peer-reviewed publications.
  • Key numbers: hema.to supports over 5k diagnoses, offering 99.7% accuracy for strong infiltration cases. Also, more than 75% of cases potentially don't require human intervention.

Video ▢️

Awards & Recognitions πŸ†

  • 2022 Medical Valley Innovation Night: First prize πŸ”—

Quotes πŸ’¬

We have been convinced by the founding team, composed of three former entrepreneurs from the same company, with three PhD profiles, at a stage where they are going to scale their go to market, which is coherent with our deep tech seed investment thesis. I rejoice because hema.to is Elaia's first investment in Germany.
Anne-Sophie Carrese, Managing Partner at Elaia Partners πŸ”—
Last update: July 11, 2023